RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $49
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $46 to $49.
Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says
Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities.
Analyst Ratings for Xenon Pharmaceuticals
Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter:
4 Analysts Have This to Say About Xenon Pharmaceuticals
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:
Xenon Pharmaceuticals: Q2 Earnings Insights
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Xenon Pharmaceuticals Q2 EPS $(0.55) Misses $(0.48) Estimate
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.48) by 14.58 percent. This is a 7.84 percent decrease over losses of $(0.51) per share
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $41
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $47 to $41.
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI’s Brain Cancer Vaccine, Xenon’s Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours: